Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028483 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
A Phase 2 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00028483: Clinical Trial Phase 2 study, sponsored by Seagen.
NCT00028483 is a Phase 2 study that was terminated before completion, run by Seagen. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028483, a Phase 2 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and monoclonal antibody therapy in treating women who have metastatic or recurrent breast cancer.
Interventions
- DRUG docetaxel
- DRUG cBR96-doxorubicin immunoconjugate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
Why NCT00028483 stopped before completion
NCT00028483 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00028483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00028483 about?
NCT00028483 is a clinical study titled "Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may ...
What is the current status of trial NCT00028483?
This trial is currently terminated. It is a Phase 2 study. The study started on 2000-10. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00028483?
The interventions under investigation include: docetaxel (DRUG), cBR96-doxorubicin immunoconjugate (DRUG).
Who is sponsoring clinical trial NCT00028483?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia